Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Add filters

Document Type
Year range
Current Bioactive Compounds ; 19(5):17-25, 2023.
Article in English | EMBASE | ID: covidwho-2267434


Hesperidin has gained major interest recently due to the outbreak of COVID-19. The traction has led to more research being conducted on the compound hesperidin. Recent studies have shown its anti-inflammatory and anti-viral attributes, which have beneficial effects on severe acute respiratory syndrome (SARS-CoV-2). Hesperidin has also shown unique effects on the protein of SARS-CoV-2, which lead to a good preventative measure for SARS-CoV-2. Hesperidin also causes a suppression of appetite, which helps to combat obesity through the release of cholecystokinin. Furthermore, hesperidin has shown cardioprotective properties, which cause an increase in plasma high-density lipoprotein levels and a decrease in plasma low-density lipoprotein levels. Hesperidin is also used in combination with the Japanese herb Rikkunshito, which has shown potential in a discovery of a new drug for gastrointestinal motility as hesperidin can depolarize pacemaker potential in interstitial cells of Cajal (ICC). The chemo-preventive effects of hesperidin are caused by its antioxidant effect, which may prevent tissue necrosis due to oxidative stress. The photo-protective effect of hesperidin can reduce the damage to the skin caused by UV rays. Hesperidin also possesses wound-healing properties.Copyright © 2023 Bentham Science Publishers.

Journal of Medical Pharmaceutical and Allied Sciences ; 10(1):2653-2657, 2021.
Article in English | Scopus | ID: covidwho-1190727


To assess the impact of single chamber right ventricular pacing on the clinical profiles, QRS morphology and QRS duration on electrocardiogram. This prospective study was conducted to evaluate clinical profile, QRS morphology and QRS duration of patients are having a atrioventricular disease, undergoing single chamber pacemaker implantation between November 2017 to January 2019 at UNMICRC, Ahmedabad, Gujarat. All patients were followed up biannually. At each follow-up visit clinical features were assessed, and pacemaker interrogation, electrocardiography was done. Results: Out of 135 patients, 98 patients completed 12 months follow -up and were included in final analysis. Mean age was 65.92 ± 9.64 years with 60.2% male. Most common comorbidity was hypertension (49.5%) followed by diabetes mellitus type II (24.5%), coronary artery disease (9.2%), hypothyroidism (4.1%) and cerebro vascular accident (2.0%). The Commonest indication for pacemaker was complete heart block (85.7%) followed by high degree Atrioventricular (AV) block (14.3%). 35.7% and 40.8% patients had presyncope and syncope. About 16.3% and 7.1% patients had New York Heart Failure Association (NYHA 2) and (NYHA 3) grade dyspnea. In the present study, baseline QRS was 155.63 ± 15.70 ms which increased to 164.79 ± 10.69 ms at 12 month follow- up (p = 0.0001). All except 4 patients had Left Bundle Branch Block (LBBB) on baseline of electrocardiogram ECG. The QRS duration increases over one year followup. The patients remain asymptomatic for heart failure and arrhythmias on follow-up. © 2021 Journal of Medical Pharmaceutical and Allied Sciences. All rights reserved.